Keyphrases
4E-BP1
12%
Anti-tumor Response
12%
Bevacizumab
100%
Bone Sarcoma
12%
Brain Tumor
12%
Co-treatment
12%
Dose Level
25%
Dose-limiting Toxicity
37%
Everolimus
100%
Mammalian Target of Rapamycin (mTOR)
25%
Mammalian Target of Rapamycin Pathway
12%
Maximum Tolerated Dose
25%
Overall Survival
12%
Peripheral Blood Mononuclear Cells
25%
Phase 1 Study
12%
Phase 1 Trial
100%
Phase Current
12%
Phospho-Akt
12%
Progression-free Survival
12%
Progressive Disease
12%
Refractory Solid Tumors
12%
Soft Tissue
12%
Solid Tumors
100%
Stable Disease
12%
Tumor
12%
Vascular Endothelial Growth Factor
12%
Pharmacology, Toxicology and Pharmaceutical Science
Bevacizumab
100%
Biological Marker
12%
Diseases
25%
Dose Toxicity
12%
Everolimus
100%
Intracranial Tumor
12%
Mammalian Target of Rapamycin
37%
Maximum Tolerated Dose
25%
Neoplasm
12%
Osteosarcoma
12%
Overall Survival
12%
Progression Free Survival
12%
Solid Malignant Neoplasm
100%
Vasculotropin A
12%
Medicine and Dentistry
Bevacizumab
100%
Biological Marker
12%
Diseases
12%
Everolimus
100%
Mechanistic Target of Rapamycin
37%
Neoplasm
12%
Osteosarcoma
12%
Overall Survival
12%
Peripheral Blood Mononuclear Cell
25%
Progression Free Survival
12%
Progressive Disease
12%
Solid Malignant Neoplasm
100%
Vasculotropin A
12%